Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in oncological medicine 2019-01, Vol.2019 (2019), p.1-3
Hauptverfasser: Bersanelli, Melissa, Cannita, Katia, Cortellini, Alessio, Parisi, Alessandro, Ficorella, Corrado
Format: Artikel
Sprache:eng
Schlagworte:
Apoptosis
Bladder cancer
Cancer therapies
Case Report
Case reports
Chemotherapy
Clinical medicine
Hemodialysis
Immunotherapy
Kidney diseases
Lymphatic system
Medical imaging
Metastasis
Monoclonal antibodies
Patients
Targeted cancer therapy
Urology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab.
ISSN:2090-6706
2090-6714
DOI:10.1155/2019/3452762